DOI QR코드

DOI QR Code

The Ability of FDG Uptake Ratio and Glut-1 Expression to Predict Mediastinal Lymph Node Metastasis in Resected Non-small Cell Lung Cancer

절제된 비소세포암에서 FDG 섭취비와 Glut-1 발현 정도를 이용한 종격동 림프선 전이 여부 예측

  • Cho, Suk-Ki (Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University) ;
  • Lee, Eung-Bae (Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University)
  • 조석기 (경북대학교 의학전문대학원 흉부외과학교실) ;
  • 이응배 (경북대학교 의학전문대학원 흉부외과학교실)
  • Received : 2010.04.19
  • Accepted : 2010.08.17
  • Published : 2010.10.05

Abstract

Background: This study was designed to evaluate the FDG uptake ratio of mediastinal node and primary tumors using integrated PET/CT imaging combined with Glut-1 expression of the primary tumor in order to predict the N2 status more accurately in NSCLC patients. Material and Method: Patients who underwent integrated PET/CT scanning with a detectable mSUV for both primary tumors and mediastinal lymph nodes were eligible for this study. The FDG uptake ratio between the mediastinal node and the primary tumor was calculated. Result: The average mSUV of primary tumors and mediastinal nodes were, respectively, $7.4{\pm}2.2$ and $4.2{\pm}2.2$ in N2-positive patients and $7.6{\pm}3.7$ and $2.8{\pm}6.9$ in N2-negative patients. The mean FDG uptake ratio of mediastinal node to primary tumor were $0.58{\pm}0.23$ for malignant N2 lymph nodes and $0.45{\pm}0.20$ for benign lymph nodes (p<0.05). Models which combined Glut-1 expression with an FDG ratio have better diagnostic power than models that use the FDG uptake ratio alone. Conclusion: In some patients with a previous history of pulmonary tuberculosis or other inflammatory lung diseases, an FDG uptake ratio combined with Glut-1 expression may be useful in diagnosing mediastinal node metastasis more exactly.

배경: 이 연구는 비소세포암 환자에서 종격동 임파선 전이 여부를 정확히 예측하기 위해서 PET/CT에서 종격동 임파선과 폐종괴의 FDG 섭취비와 폐종괴의 Glut-1 발현 정도를 이용하여 분석 하고자 하였다. 대상 및 방법: PET/CT에서 폐종괴와 종격동 임파선에서 측정할 수 있는 정도의 FDG섭취가 있는 환자를 대상으로 하였다. FDG 섭취비는 종격동 임파선의 섭취를 폐종괴의 섭취로 나누어 구하였다. 폐종괴의 Glut-1 발현은 발현 면적으로 나타내었다. 결과: 폐종괴와 종격동 임파선의 mSUV값은 악성군에서 각각 $7.4{\pm}2.2$$4.2{\pm}2.2$, 양성군에서 각각 $7.6{\pm}3.7$$2.8{\pm}6.9$였다. FDG의 섭취비는 악성군과 양성군에서 각각 $0.58{\pm}0.23$$0.45{\pm}0.20$ (p<0.05)였다. FDG 섭취비와 Glut-1 발현 정도를 결합한 모델 중에서 {p/(1-p)}=ratio+glut+ratio${\times}$glut의 식으로 표시된 모델이 FDG 섭취비만을 이용한 모델 보다 정확히 종격동 임파선의 악성 정도를 예측할 수 있었다. 결론: 염증성 폐질환의 병력이 있는 일부 폐암 환자에서 Glut-1 발현 정도를 고려한 FDG 섭취비를 분석한 모델은 종격동 임파선의 악성 정도를 정확히 진단할 수 있다.

Keywords

References

  1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. https://doi.org/10.1378/chest.111.6.1710
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. https://doi.org/10.3322/canjclin.57.1.43
  3. DeCamp MM Jr, Ashiku S, Thurer R. The role of surgery in N2 non-small cell lung cancer. Clin Cancer Res 2005;11: 5033s-7s. https://doi.org/10.1158/1078-0432.CCR-05-9013
  4. Silvestri GA, Gould MK, Margolis ML, et al. Non-invasive staging of non-small cell lung cancer: ACCP evidencedbased clinical practice guidelines. 2nd ed. Chest 2007; 132: 178s-201s. https://doi.org/10.1378/chest.07-1360
  5. Hara M, Shiraki N, Itoh M, et al. A problem in diagnosing N3 disease using FDG-PET in patients with lung cancer: high false positive rate with visual assessment. Ann Nucl Med 2004;18:483-8. https://doi.org/10.1007/BF02984564
  6. Shim SS, Lee KS, Kim BT, et al. Focal parenchymal lung lesions showing a potential of false-positive and falsenegative interpretations on integrated FDG PET/CT. AJR Am J Roentgenol 2006;186:639-48. https://doi.org/10.2214/AJR.04.1896
  7. Ohtsuka T, Nomori H, Watanabe K, et al. False-positive findings on [18F] FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2005;35:271-3. https://doi.org/10.1093/jjco/hyi072
  8. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]-FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27:1778- 85. https://doi.org/10.1007/s002590000367
  9. Groth SS, Whitson BA, Maddaus MA. Radiographic staging of mediastinal lymph nodes in non-small cell lung cancer patients. Thorac Surg Clin 2008;18:349-61. https://doi.org/10.1016/j.thorsurg.2008.07.002
  10. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71. https://doi.org/10.1378/chest.08-0978
  11. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall cell carcinoma. Ann Thorac Surg 2007;83:1826-9. https://doi.org/10.1016/j.athoracsur.2006.12.034
  12. Kim YK, Lee KS, Kim BT, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country. Cancer 2007; 109:1068-77. https://doi.org/10.1002/cncr.22518
  13. Cho S, Ryu KM, Lee HJ, et al. Glut1 expression and FDG uptake in non-small cell lung carcinoma: Its relationship to Histopathologic types and proliferation rate. J Lung Cancer 2005;4:107-14.